MSF Field Research >
1 Published Research and Commentary >
Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries.
this identifier to cite or link
to this item:
|Download this article:|
|Lancet inf dis Rony CTX.pdf||116Kb||Adobe PDF|
|Title: ||Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries.|
|Affiliation: ||Médecins Sans Frontières, Medical department (Operational Research), Brussels Operational Center, Brussels, Belgium. email@example.com|
|Citation: ||Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries. 2007, 7 (10):686-93notLancet Infect Dis|
|Journal: ||The Lancet Infectious Diseases|
|Issue Date: ||Oct-2007 |
|PubMed ID: ||17897611|
|Additional Links: ||http://www.thelancet.com/journals/laninf|
|Abstract: ||Co-trimoxazole (trimethoprim-sulfamethoxazole) is a widely available antibiotic that substantially reduces HIV-related morbidity and mortality in both adults and children. Prophylaxis with co-trimoxazole is a recommended intervention of proven benefit that could serve not only as an initial step towards improving paediatric care in young children with limited access to antiretroviral treatment, but also as an important complement to antiretroviral therapy in resource-limited settings. Despite co-trimoxazole's known clinical benefits, the potential operational benefits, and favourable recommendations by WHO, UNAIDS, and UNICEF, its routine use in developing countries--particularly sub-Saharan Africa--has remained limited. Out of an estimated 4 million children in need of co-trimoxazole prophylaxis (HIV-exposed and HIV-infected), only 4% are currently receiving this intervention. We discuss some of the major barriers preventing the scale-up of co-trimoxazole prophylaxis for children in countries with a high prevalence of HIV and propose specific actions required to tackle these challenges.|
|MeSH: ||AIDS-Related Opportunistic Infections|
|Rights: ||Reproduced on this site with permission of Elsevier Ltd. Please see www.TheLancet.com/journals/laninf for further relevant comment.|
|Appears in topics: ||HIV/AIDS|
|Related articles on PubMed|
Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda.
Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, Kaharuza F, Culver D, Kizito F, Bunnell R, Kigozi A, Nakanjako D, Wafula W, Quick R
2004 Oct 16-22
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis.
Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, Walensky RP, Weinstein MC, Toure S, Smith HE, Kaplan JE, Freedberg KA, Global AIDS Policy Model Investigators
2005 Aug 12
Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial.
Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, Farrelly L, Kaganson N, Zumla A, Gillespie SH, Nunn AJ, Gibb DM, CHAP trial team
2004 Nov 20-26
|See all 109 articles|
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.